The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).
On February 4, 2025, Quantum BioPharma announced the successful results of a clinical trial for its product unbuzzd™, which significantly accelerates alcohol metabolism and alleviates symptoms of intoxication. The trial, which involved a double-blind, placebo-controlled crossover study, demonstrated that unbuzzd™ reduces blood alcohol concentration more than 40% faster than placebo, enhances alertness, and mitigates hangover effects without side effects. This development is expected to have positive implications for the company’s market positioning and offers a promising solution for alcohol intoxication management.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders as well as alcohol misuse disorders. Through its subsidiary, Lucid Psycheceuticals Inc., the company is working on Lucid-MS, a compound aimed at treating multiple sclerosis. Quantum BioPharma also invented the dietary supplement unbuzzd™, which accelerates alcohol metabolism, and has licensed its OTC version to Celly Nutrition Corp.
YTD Price Performance: -23.77%
Average Trading Volume: 113,444
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.99M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.